Summit pulls $500M share sale a day after announcing it

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

By Jonathan Gardner • June 11, 2026

GSK boosts cancer pipeline with $11B Nuvalent buyout

The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

By Jonathan Gardner • June 9, 2026

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

By Ben Fidler • June 8, 2026

Incyte to buy blood disorder drug in possibly $2B deal

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

By Jacob Bell • June 8, 2026

Alnylam, Inceptive ink AI deal potentially worth $2B

The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.

By Kristin Jensen • June 4, 2026

Lilly, Ascidian link up in RNA exon editing pact

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.

By Gwendolyn Wu • June 3, 2026

Servier buys into muscular dystrophy with potentially $2.7B deal

The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.

By Jacob Bell • June 1, 2026

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

By Ben Fidler • May 29, 2026

Lilly dives into vaccine research with 3 biotech buyouts

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

By Delilah Alvarado • May 26, 2026

Lilly snaps up Engage to advance non-viral genetic medicines

The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

By Delilah Alvarado • May 20, 2026

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.

By Jacob Bell • May 19, 2026

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

By Delilah Alvarado • May 12, 2026

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts. 

By Ben Fidler • May 12, 2026

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

By Delilah Alvarado • May 11, 2026

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

By Kelly Bilodeau • May 8, 2026

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

By Gwendolyn Wu • May 7, 2026

Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B

Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.

By Elise Reuter • May 7, 2026

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

By Ben Fidler • May 1, 2026

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

By Jonathan Gardner • April 30, 2026

Teva nabs experimental Tourette drug in $700M Emalex buyout

A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business. 

By Jacob Bell • April 29, 2026

Chiesi to buy KalVista in $1.9B deal for rare disease drug

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.

By Kristin Jensen • April 29, 2026

Lilly to buy startup Ajax in bid for a better JAK drug

Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.

By Ben Fidler • April 27, 2026

Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s currently in early-stage testing for multiple myeloma.

By Ben Fidler • April 20, 2026

UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B

The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common epilepsy.

By Jacob Bell • April 17, 2026

Obsidian, Galera to advance cell therapy following reverse merger

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement expected to deliver $350 million in gross proceeds.

By Jacob Bell • April 15, 2026